Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
Innovent has granted Roche exclusive global rights to develop, manufacture and commercialize IBI3009
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
Merck has also decided to end the favezelimab clinical development program
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Subscribe To Our Newsletter & Stay Updated
